BACKGROUND: Vascular endothelial growth factor (VEGF) is involved in angiogenesis. We investigated the association of VEGF serum levels (pre-treatment and follow-up) with outcome in patients with melanoma. PATIENTS AND METHODS: Serum levels of VEGF in melanoma patients at diagnosis and during follow-up were analysed with enzyme-linked immunoassays. Patients were followed up with physical examination and ultrasound scans of the liver every three months and thorax X-ray annually. The VEGF serum level was evaluated six-monthly. RESULTS: From February 1996 to February 2000, 33 patients were enrolled. Ninety-two serum blood samples were collected. Patients had a median age of 60 years (range 32-82). Twenty patients were males, 13 females. One patient presented with stage IA disease, 2 with stage IB, 11 with stage IIA, 4 with stage IIB, 8 with stage III and 5 with stage IV. Two patients were affected by uveal melanoma. The melanomas were predominantly located at the extremities or trunk (26/33). The median serum level of VEGF at diagnosis was 249 ng/ml (minimum: 9 ng/ml, maximum: 1215 ng/ml). The median survival of all 33 patients was 45.1 months. The median time-to-progression was 36.7 months. Patients with lower or higher serum VEGF values showed no statistically significant differences in survival. In contrast, high serum VEGF values were associated with shorter disease-free survival as compared with lower values (median DFS: 25 vs 60 months, p = 0.048 at log-rank test). CONCLUSION: Our results suggest that serum VEGF could be of prognostic value in melanoma.
BACKGROUND:Vascular endothelial growth factor (VEGF) is involved in angiogenesis. We investigated the association of VEGF serum levels (pre-treatment and follow-up) with outcome in patients with melanoma. PATIENTS AND METHODS: Serum levels of VEGF in melanomapatients at diagnosis and during follow-up were analysed with enzyme-linked immunoassays. Patients were followed up with physical examination and ultrasound scans of the liver every three months and thorax X-ray annually. The VEGF serum level was evaluated six-monthly. RESULTS: From February 1996 to February 2000, 33 patients were enrolled. Ninety-two serum blood samples were collected. Patients had a median age of 60 years (range 32-82). Twenty patients were males, 13 females. One patient presented with stage IA disease, 2 with stage IB, 11 with stage IIA, 4 with stage IIB, 8 with stage III and 5 with stage IV. Two patients were affected by uveal melanoma. The melanomas were predominantly located at the extremities or trunk (26/33). The median serum level of VEGF at diagnosis was 249 ng/ml (minimum: 9 ng/ml, maximum: 1215 ng/ml). The median survival of all 33 patients was 45.1 months. The median time-to-progression was 36.7 months. Patients with lower or higher serum VEGF values showed no statistically significant differences in survival. In contrast, high serum VEGF values were associated with shorter disease-free survival as compared with lower values (median DFS: 25 vs 60 months, p = 0.048 at log-rank test). CONCLUSION: Our results suggest that serum VEGF could be of prognostic value in melanoma.
Authors: Kriti Mittal; Henry Koon; Paul Elson; Pierre Triozzi; Afshin Dowlati; Helen Chen; Ernest C Borden; Brian I Rini Journal: Cancer Biol Ther Date: 2014-05-19 Impact factor: 4.742
Authors: Julie M Roda; Laura A Sumner; Randall Evans; Gary S Phillips; Clay B Marsh; Timothy D Eubank Journal: J Immunol Date: 2011-07-15 Impact factor: 5.422
Authors: Richard D Carvajal; Michael K Wong; John A Thompson; Michael S Gordon; Karl D Lewis; Anna C Pavlick; Jedd D Wolchok; Patrick B Rojas; Jonathan D Schwartz; Agop Y Bedikian Journal: Eur J Cancer Date: 2014-06-12 Impact factor: 9.162
Authors: Heather K Hamilton; Amy E Rose; Paul J Christos; Richard L Shapiro; Russell S Berman; Madhu Mazumdar; Michelle W Ma; Daniel Krich; Leonard Liebes; Peter C Brooks; Iman Osman Journal: J Transl Med Date: 2010-02-23 Impact factor: 5.531
Authors: John S Rudge; Jocelyn Holash; Donna Hylton; Michelle Russell; Shelly Jiang; Raymond Leidich; Nicholas Papadopoulos; Erica A Pyles; Al Torri; Stanley J Wiegand; Gavin Thurston; Neil Stahl; George D Yancopoulos Journal: Proc Natl Acad Sci U S A Date: 2007-11-13 Impact factor: 11.205
Authors: Julie M Roda; Yijie Wang; Laura A Sumner; Gary S Phillips; Clay B Marsh; Timothy D Eubank Journal: J Immunol Date: 2012-08-06 Impact factor: 5.422